Drug intelligence / Profile preview

NCTX

Development stage: Phase 1
Lead developer: Marval Pharma
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

NCTX is a PEGylated Liposomal Iodixanol Injection developed by Marval Pharma Ltd. It is designed as a diagnostic agent for use in computed tomography (CT) scans. The drug is administered intravenously to healthy volunteers in a Phase 1 study to evaluate its safety, tolerability, and pharmacokinetics. Its primary function is to enhance radiographic density in regions of interest (ROI) for imaging purposes.

Other names: PEGylated Liposomal Iodixanol Injection

Beyond the preview

Go deeper on NCTX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCTX.

Explore the full profile